Price Target Archives - Page 79 of 2160

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

COIN

2 minute read

Wall Street’s Most Accurate Analysts’ Views On 3 Financial Stocks With Over 6% Dividend Yields

By Avi Kapoor

April 10, 8:13 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

MAIN

2 minute read

Fastenal Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

By Avi Kapoor

April 10, 5:18 AM

Fastenal Company (NASDAQ: FAST) is scheduled to release earnings results for its first quarter (Q1), before the opening bell on April 11, 2024.

FAST

2 minute read

Bitdeer Leads in Bitcoin Mining, Analyst Points to Growth Catalysts Including Proprietary Tech and Strategic Data Centers

By Anusuya Lahiri

April 9, 3:44 PM

Analyst initiates coverage on BTDR with Buy rating and $10.5 price target. BTDR has strong growth strategy, cheap power, diverse revenue, and proprietary tech. Bitcoin halving and ETFs may benefit quality players like BTDR.

BTDR

2 minute read

If Tesla Hits Brakes On $25K EV, It ‘Would Be A Meaningful Negative For The Stock’: Goldman Sachs

By Chris Katje

April 9, 3:03 PM

Tesla stock is sized up by an analyst after disappointing q1 delivery figures and reports of a delay in its low-cost vehicle model.

TSLA

2 minute read

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says

By Vandana Singh

April 9, 2:26 PM

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.

ELVN

2 minute read

Alkermes’ Sleeping Disorder Studies’ Data Look Excellent, Analyst Says

By Vandana Singh

April 9, 2:23 PM

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

ALKS

2 minute read

Sensata Technologies Faces Challenges Navigating EV Headwinds, Goldman Sachs Analyst Warns

By Nabaparna Bhattacharya

April 9, 2:23 PM

Goldman Sachs downgrades Sensata Technologies due to EV sales slowdown and production delays, citing pressured fundamentals.